Nms-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity in Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases.
Fogliatto, G., Gianellini, L.M., Brasca, M.G., Casale, E., Ballinari, D., Ciomei, M., Degrassi, A., De Ponti, A., Germani, M., Guanci, M., Paolucci, M., Polucci, P., Russo, M., Sola, F., Valsasina, B., Visco, C., Zuccotto, F., Donati, D., Felder, E., Pesenti, E., Mantegani, S., Galvani, A., Isacchi, A.(2013) Clin Cancer Res 19: 3520
- PubMed: 23674492 
- DOI: https://doi.org/10.1158/1078-0432.CCR-12-3512
- Primary Citation of Related Structures:  
4B7P - PubMed Abstract: 
Recent developments of second generation Hsp90 inhibitors suggested a potential for development of this class of molecules also in tumors that have become resistant to molecular targeted agents. Disease progression is often due to brain metastases, sometimes related to insufficient drug concentrations within the brain. Our objective was to identify and characterize a novel inhibitor of Hsp90 able to cross the blood-brain barrier (BBB).
Organizational Affiliation: 
Department of Biotechnology, Nerviano Medical Sciences Srl, Nerviano (MI), Italy. gianpaolo.fogliatto@nervianoms.com